Mosaic Therapeutics has closed its $28 million series A funding round and appointed former Novartis Oncology SVP Brian Gladsden as CEO. The Series A funding will be used to further advance Mosaic’s pipeline of targeted oncology therapies for biomarker-stratified populations, progressing its lead programmes through preclinical development to IND-enabling studies. Read More
The UK’s National Institute for Health and Clinical Excellence (NICE) has recommended that Lynparza (olaparib) can be used for NHS patients with both early-stage breast cancer and prostate cancer. Olaparib is PARP inhibitor that targets cancers linked to faulty BRCA1 or BRCA2 genes and works across many different cancer types. The… Read More
Ahead of attending the American Association for Cancer Research (AACR) annual meeting from 14-19 April, 2023 at the Orange County Convention Center in Orlando, Florida, DDW’s Megan Thomas outlines what to expect from the event. Programme highlights The topic tracks include everything from clinical trials, drug development, immunology and bioinformatics,… Read More
Avacta Group has dosed its first patient in the fifth cohort of the first-in-human Phase I trial (ALS-6000-101) of AVA6000 in solid tumours. This follows the approval of an amended clinical trial protocol by the UK’s Medical and Healthcare Products Regulatory Agency (MHRA) to allow for… Read More
DDW Editor Reece Armstrong speaks to Howard Davis, CEO of clinical stage oncology company, Akamis Bio, about its work in developing a gene therapy to treat pancreatic cancer. In February this year, Akamis Bio announced an expansion of its ongoing partnership with the Parker Institute for Cancer Immunotherapy (PICI) to include… Read More
Italian research institute and contract research organisation IRBM has become the only company from outside the United States to join cancer drug discovery network the Chemical Biology Consortium (CBC). The CBC is the discovery engine of the National Cancer Institute (NCI) Experimental Therapeutics (NExT) Program, administered… Read More
CureSearch for Children’s Cancer, a national non-profit with a mission to end childhood cancer by driving targeted and innovative research in an accelerated time frame, will fund a Phase I clinical trial to bring new therapies to paediatric brain cancer patients, including those with limited or no treatment options. Read More
A new, oral, first-in-class experimental cancer drug has shown potent activity against cancer cells and caused shrinkage of hard-to-treat human ovarian tumours grown in mice, a new study shows. The drug, which is now called NXP800 and has already entered a Phase I clinical trial, was… Read More
Companies Evergreen Discovery and Orbit Discovery have entered into a collaboration to identify specific cell targeting peptides and advance the development of novel radiopharmaceuticals. The agreement covers activities including designing peptide libraries, hit identification and hit validation to confirm cell surface binding properties. The radiopharmaceuticals market is rapidly expanding with… Read More
Hosted by DDW and supported by Tecan, “How next-generation sequencing is informing oncology drug discovery” will be free to attend on April 24 at 7AM PST / 10AM EST / 3PM BST / 4PM CET. Join this free webinar to learn about the… Read More
Watch this free webinar to learn about the biggest challenges and opportunities facing the NGS oncology space. You will hear from Darrell Green, a lecturer in RNA Biology at Norwich Medical School, Panna Sharma, CEO of Lantern Pharma, as well as Dr Stephane Budel and Dr… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. As March draws to a close, this week’s key announcements have demonstrated the breadth of… Read More
New data has revealed a long-term response in patients with advanced non-small cell lung cancer (NSCLC) taking Rybrevant (amivantamab). The CHRYSALIS study is evaluating amivantamab in patients with advanced non-small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease… Read More
A Phase II trial to investigate onvansertib for the second line treatment of patients with KRAS/NRAS-mutated metastatic colorectal cancer (mCRC) has treated its first patients. The ONSEMBLE trial is designed to demonstrate a clinically meaningful difference in response and onvansertib’s contribution to standard of care (SoC)… Read More
News round-up for 27-31 March by DDW Digital Content Editor Diana Spencer. As March draws to a close, this week’s key announcements have demonstrated the breadth of international approaches to tackling cancer, with vaccines, proenzymes, immunotherapies and antibody-based treatments all currently under investigation around the world. The… Read More
Today is #WearAHatDay created by Brain Tumour Research to raise awareness and funds for research into finding treatments for brain cancer. Brain Tumour Research encourages people to “look super for science and help research breakthroughs happen”. Over the last ten years, Wear A Hat Day events have raised more than… Read More
